問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Others-Department of Medical Imaging

Division of Radiology

Division of Radiation Therapy

Digestive System Department

Division of General Internal Medicine

Division of Urology

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Radiology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Radiology

更新時間：2023-09-19

梁博欽-, -
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

梁博欽

List

56Cases

2011-09-01 - 2013-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-03-31 - 2019-04-30

Phase III

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

  • Condition/Disease

    Unresectable Hepatocellular Carcinoma

  • Test Drug

    Lenvatinib

Participate Sites
12Sites

Not yet recruiting12Sites

2007-12-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-12-01 - 2014-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2008-10-31 - 2010-06-15

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-11-15 - 2011-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-08-23 - 2020-07-31

Phase II

A phase II, Multi-Center, Open-Label, Single-Arm Study to evaluate the clinical validity and safety of IOP injection for magnetic resonance imaging (MRI) contrast agent in patients with Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    IOP injection

Participate Sites
8Sites

Not yet recruiting6Sites

Terminated1Sites

2011-03-15 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2015-07-01 - 2022-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Ramucirumab (Cyramza)

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

2011-01-10 - 2013-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB